Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 14/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | PER2 | O15055 | 1/20 | 0.34 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.34 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1896263 | 0.90 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL993040 | 0.87 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL992716 | 0.87 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3LMNACETP | |
| SCHEMBL995174 | 0.81 | SLC6A2 (0.51) | SLC6A2SLC6A4LMNACETP | |
| SCHEMBL993525 | 0.80 | IDH1 (0.35) | CETP | |
| SCHEMBL993039 | 0.79 | SLC6A2 (0.44) | SLC6A2SLC6A4LMNACETP | |
| SCHEMBL992714 | 0.79 | CETP (0.55) | CETP | |
| SCHEMBL993148 | 0.77 | CETP (0.59) | CETP | |
| SCHEMBL1901254 | 0.77 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5670533 | 0.75 | CETP (0.43) | SLC6A2SLC6A4LMNACETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010018446-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2001-08-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018446-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | SLC6A2 993/4885SLC6A4 1073/4885SLC6A3 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.